retatrutide mechanism of action triple agonist glp-1 gip glucagon Retatrutide, a agonist, delivered 30.3% weight loss at two years in Phase 3. The headlines state: → 70 lbs average loss on 12mg at 80 weeks (28.3% body weight) → From Obesity to Metabolic Health:

However, without robust appetite modulation, the long-term effect on body composition may be limited

The study design incorporated two reference groups (diabetes and overweight/obese), to reduce the influence of potential confounding variables

2024) (Table 1)

New research indicates that these autoantibodies may damage the nerves in your stomach

In this study, both the GLP-1MK-801-treated mice and the calorie-restricted mice exhibited improved insulin sensitivity relative to the vehicle treatment and both monotherapy control groups (Extended Data Fig

Much depends on their overall health, how the medications affect their cycles and what their goals are for building a family